What is Unity Biotechnology Inc. (UBX) Stock Return on Shareholders’ Capital?

Unity Biotechnology Inc. (NASDAQ: UBX) stock fell -5.00% on Friday to $0.43 against a previous-day closing price of $0.45. With 1.29 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.82 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.4400 whereas the lowest price it dropped to was $0.4200. The 52-week range on UBX shows that it touched its highest point at $3.64 and its lowest point at $0.42 during that stretch. It currently has a 1-year price target of $7.83. Beta for the stock currently stands at 0.71.

Top 5 Tech Stocks Every Investor Should Buy Right Now

While finding excellent stocks with the potential for gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Tech Stocks Every Investor Should Buy Right Now", we have identified five tech stocks we believe could appreciate.

Sign up here to get your free report now.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of UBX was down-trending over the past week, with a drop of -10.44%, but this was down by -30.26% over a month. Three-month performance dropped to -27.92% while six-month performance fell -68.25%. The stock lost -85.58% in the past year, while it has lost -70.86% so far this year. A look at the trailing 12-month EPS for UBX yields -0.95 with Next year EPS estimates of -0.80. For the next quarter, that number is -0.17. This implies an EPS growth rate of 41.00% for this year and 3.70% for next year.

Float and Shares Shorts:

At present, 140.23 million UBX shares are outstanding with a float of 137.51 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.22 million, which was 0.32% higher than short shares on Jun 14, 2022. In addition to Dr. Anirvan Ghosh Ph.D. as the firm’s CEO & Director, Dr. Nathaniel E. David A.B., Ph.D. serves as its Co-Founder & Exec. Director.

Institutional Ownership:

Through their ownership of 39.15% of UBX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 9.69% of UBX, in contrast to 4.39% held by mutual funds. Shares owned by individuals account for 2.35%. As the largest shareholder in UBX with 0.95% of the stake, The Vanguard Group, Inc. holds 1,268,108 shares worth 1,268,108. A second-largest stockholder of UBX, Renaissance Technologies LLC, holds 957,718 shares, controlling over 0.72% of the firm’s shares. Fidelity Management & Research Co is the third largest shareholder in UBX, holding 934,010 shares or 0.70% stake. With a 0.57% stake in UBX, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 764,789 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.38% of UBX stock, is the second-largest Mutual Fund holder. It holds 503,319 shares valued at 0.23 million. Edinburgh Worldwide Investment Tr holds 0.26% of the stake in UBX, owning 341,111 shares worth 0.16 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for UBX since 6 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With UBX analysts setting a high price target of $12.00 and a low target of $3.00, the average target price over the next 12 months is $7.83. Based on these targets, UBX could surge 2690.7% to reach the target high and rise by 597.67% to reach the target low. Reaching the average price target will result in a growth of 1720.93% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. UBX will report FY 2022 earnings on 03/15/2023. Analysts have provided yearly estimates in a range of -$0.44 being high and -$0.86 being low. For UBX, this leads to a yearly average estimate of -$0.75. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Unity Biotechnology Inc. surprised analysts by $0.07 when it reported -$0.19 EPS against a consensus estimate of -$0.26. The surprise factor in the prior quarter was -$0.03. Based on analyst estimates, the high estimate for the next quarter is -$0.11 and the low estimate is -$0.22. The average estimate for the next quarter is thus -$0.17.

Summary of Insider Activity:

Insiders traded UBX stock several times over the past three months with 0 Buys and 3 Sells. In these transactions, 0 shares were bought while 26,993 shares were sold. The number of buy transactions has increased to 4 while that of sell transactions has risen to 12 over the past year. The total number of shares bought during that period was 283,333 while 110,759 shares were sold.

Leave a Comment

Your email address will not be published.